Johnson & Johnson (NYSE:JNJ) said today it launched its Cerenovus brand, which combined its Pulsar Vascular and Neuravi acquisitions and its remaining Codman Neuro neurological portfolio.
Cerenovus was launched at the European Society of Minimally Invasive Neurological Therapy’s 9th annual meeting, J&J said.
Johnson & Johnson said that the Cerenovus product portfolio aims to help improve stroke care, with the number of strokes annually projected to rise from 1.1 million in 2000 to 1.5 million by 2025.
“We believe stroke should not be a life sentence. Cerenovus is inspired by our long heritage and dedication to improving patient lives. We believe there is no other healthcare company better positioned than us to assist in addressing the real pain points for doctors who treat stroke – from helping them work more efficiently; to achieving a higher success rate across all neurovascular cases,” J&J EMEA cardiovascular specialty solutions VP Gabriele Fischetto said in a press release.
Johnson & Johnson originally announced the formation of Cerenovus in late July, which was renamed in part to coincide with the company’s $1 billion divestiture of its Codman neurosurgery business to Integra Lifesciences.
J&J’s Codman Neuro unit paid an undisclosed amount last December for Pulsar Vascular and its PulseRider device for treating brain aneurysms. PulseRider is designed to shore up the blood vessels around wide-necked aneurysms at or near a bifurcation of the basilar tip or carotid terminus and facilitate the implantation of an embolization coil, without obstructing blood flow through the vessels.
In April, the unit acquired Neuravi and its portfolio of neurovascular therapy technology, also for an undisclosed amount. Neuravi makes the EmboTrap and EmboTrap II revascularization platforms designed capture clots and allow blood flow to resume immediately after the clot has been secured in stroke patients.
